Alyeska Investment Group
MRSN

Alyeska Investment Group’s Mersana Therapeutics MRSN Stock Holding History

Alyeska Investment Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,000
Closed -$1.75M – 507
2017
Q2 		$1.75M Buy
+5,000
New +$1.73M 0.01% 359

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group's MRSN Position: Q3 2017 in Review

Alyeska Investment Group sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 5,000 shares — an estimated $1.75M sold.

Alyeska Investment Group first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $1.75M in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

  • Alyeska Investment Group reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 5,000 Mersana Therapeutics shares in Q3 2017, an estimated $1.75M.
  • Alyeska Investment Group first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
  • Alyeska Investment Group's Mersana Therapeutics position peaked at $1.75M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on Alyeska Investment Group's 13F filing for Q3 2017, filed 14 Nov 2017.